EMEA grants Ranexa brand name

California, USA-based CV Therapeutics has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa for ranolazine. "Securing approval for the Ranexa brand name in Europe provides important brand synergy in the world's two largest cardiovascular markets, the USA and the European Union," said company chief executive Louis Lange.

The agent is approved for use in Europe as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies. The product is approved for use in 375mg, 500mg and 750mg doses, administered twice daily.